| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

   
Home 
 
 News
 Irish
 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 International
 Property
 Innovation
 
 Analysis/Comment
 
 Asia Economy

RSS FEED


How to use our RSS feed

 
Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.

Welcome

Finfacts is Ireland's leading business information site and you are in its business news section.

We provide access to live business television and business related videos from: Bloomberg TV; The Wall Street Journal; CNBC and the Financial Times. Click image:

Links

Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax 2008

Climate Change Reports

Global News

Bloomberg News

CNN Money

Cnet Tech News

Newspapers

Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News

 

Feedback

 

Content Management by interactivetools.com.

News : Irish Last Updated: Apr 24, 2009 - 5:31:05 PM


US FDA panel approves return of Elan's ms drug Tysabri
By Finfacts Team
Mar 8, 2006 - 6:23:00 PM

Email this article
 Printer friendly page

Elan's share price fell more than 70% on February 28th 2005, when TYSABRI was suspended. Elan is more dependent on the return of the multiple sclerosis drug to the market than its partner Biogen Idec
Elan's multiple sclerosis drug Tysabri should return to the US market, an advisory panel from the Food and Drug Administration recommended today.

Tysabri sales were suspended on February 28, 2005 after three patients developed a serious brain and spinal cord infection and two of them died.  

The US Food and Drug Administration has been holding an advisory meeting since Monday to decide if Tysabri should return to the market and it will make a final decision at the end of the month.

Elan, and its partner US biotech firm Biogen Idec, have been seeking approval from the US Food and Drug Administration for the treatment to be sold again, with controls to quickly identify side effects. The FDA's concern is whether PML can be treated even if it is found early.

This was the second day of meetings, a large and vocal group of MS sufferers have been at the meetings saying that it's a patients right to take the medication of their choice. They say Tysabri's efficacy far outweighs its side effects.

Elan and Biogen had been running clinical trials involving 3,000 patients.

Last week, US broker Piper Jaffray's stock analyst Deborah Knobelman released results of a poll of 140 neurologists on their opinion of Tysabri. The drug had been on the US market for three months after being approved by the FDA in November 2004 until it was suspended on February 28, 2005.

Knobelman said in a research note that 59 percent of doctors surveyed said it was too soon to bring Tysabri back to the market because of limited safety data on the drug, even though 92 percent said the treatment could be a valuable therapy to some multiple sclerosis patients.

Multiple sclerosis (MS) is an incurable disease where the body's immune system attacks myelin, or the tissue that insulates nerve fibres. Tysabri clinical trials linked the drug to progressive multifocal leukoencephalopathy (PML), a rare disease found in patients with immune deficiencies where parts of the brain becomes inflamed.

Doctors said in the poll that they would use Tysabri to treat about 10 percent of multiple sclerosis patients, or when all other available treatments had failed.

Knobelman also reported that 57 percent of doctors said the risk of PML was worth using Tysabri if all other drugs failed, and that only 6 percent would use Tysabri as a first-line therapy.

Before the withdrawal of Tysabri on Monday February 28, 2005, analysts had projected Tysabri sales of $210 million for 2005, reaching a peak of $4 billion a year by 2009.
 
Biogen/Elan Stock Activity from Feb 24,2005-Mar 4, 2005
 

Biogen on Nasdaq

Elan on the NYSE
 
Date Close/Last Volume
03/04/2005 37.530 24,039,070
03/03/2005 39.330 21,433,010
03/02/2005 40.880 24,564,080
03/01/2005 41.260 52,534,460
02/28/2005 38.650 118,284,800
02/25/2005 67.280 1,979,777
02/24/2005 66.680 3,896,137
Source: Edgar
 
Date Close/Last Volume
03/04/2005 5.710 104,582,400
03/03/2005 6.650 98,643,400
03/02/2005 7.940 47,877,100
03/01/2005 7.970 86,586,100
02/28/2005 8.000 167,068,200
02/25/2005 26.900 2,374,500
02/24/2005 26.910 1,885,600

© Copyright 2007 by Finfacts.com

Top of Page

Irish
Latest Headlines
Ryanair benefits from improved customer service
Ryanair to buy 100 new Boeing 737 MAX 200
Finfacts server migration Thursday
State-owned Allied Irish Banks reports H1 2014 profit as bad loan charges plunge
Ryanair reports profit in its financial first quarter soared 152%
UK firm opens van dealership in Dublin
Ryanair reports 8% fall in full-year profit; US services to commence in 2019
Global Financial Centres Index: New York overtakes London; Dublin slips to 66 of 83 cities
Bank of Ireland reports “significant” improvement in 2013 results
Sale process of IBRC UK projects Rock and Salt completed
CRH says 2014 will be year of profit growth after reporting 2013 loss
Ryanair reports third-quarter loss
Irish Water says it saved €100m in setup costs
RSA Insurance fires two Irish executives for large loss/ accounting irregularities
Bank of Ireland will have to raise provisions by €1.4bn; AIB says it's "well capitalised"
CRH reports slightly improved third quarter
Central Bank says ownership of Newbridge Credit Union transferred to permanent tsb
Ryanair reports H1 profits rose by 1% to €602m
Dublin Web Summit: Irish Stock Exchange and NASDAQ OMX announce dual listing plan
Irish pension managed funds returned to growth during September
Dan O’Brien resigns as economics editor of The Irish Times
Central Bank says no action required on Anglo tapes revelations
Ryanair flew 9m passengers and Aer Lingus carried 1.1m in August
UK Competition Commission says Ryanair must cut Aer Lingus stake to 5%
CRH reports H1 2013 revenue dip and loss
Vodafone refunded UK after discovery of Irish tax haven deal
RBS reports half year profit; Ulster Bank posts reduced loss
Bank of Ireland cuts pretax losses in HI 2013 to €504m
Irish State-owned Allied Irish Banks reports losses of €758m in H1 2013
Service Announcement
Irish managed pension funds declined in June
VHI reports 2012 surplus of €54.3m; Health insurance made loss
Ex- Elan director says management / board "not competent to run a business"
Aer Lingus to put €140m in employees pensions fund; Ryanair apoplectic
Wednesday Newspaper Review - Irish Business News and International Stories - - May 22, 2013
Tuesday Newspaper Review - Irish Business News and International Stories - - May 21, 2013
Ryanair, Europe’s biggest low cost carrier, announced Monday record annual profits of €569m - - up 13%
Monday Newspaper Review - Irish Business News and International Stories - - May 20, 2013
Friday Newspaper Review - - Irish Business News - - May 17, 2013
Thursday Newspaper Review - Irish Business News and International Stories - - May 16, 2013